Loading...
Vaccinatiebereidheid bij jongeren
Kroese, F Euser, S Buijs, M de Bruin, M
Kroese, F
Euser, S
Buijs, M
de Bruin, M
Citations
Altmetric:
Series / Report no.
Open Access
Type
Report
Language
nl
Date of publication
2021-07-02
Year of publication
Files
Research Projects
Organizational Units
Journal Issue
Title
Vaccinatiebereidheid bij jongeren
Translated Title
Willingness to vaccinate among young people
Published in
Abstract
Het BioNTech/Pfizer vaccin is op 28 mei 2021 door het Europees Medicijn Agentschap (EMA(European Medicines Agency)) goedgekeurd voor gebruik bij jongeren tussen de 12 en 15 jaar oud. Eerder was het vaccin al goedgekeurd om personen vanaf 16 jaar in te enten. Op 9 juni 2021 is na advies van de Gezondheidsraad besloten om kinderen tussen de 12 en 18 jaar met een medisch risico het BioNTech/Pfizer vaccin aan te bieden.
Op 30 juni is na nieuw advies van de Gezondheidsraad besloten om ook gezonde kinderen tussen 12 en 18 jaar dit vaccin aan te bieden. Kinderen van 16 en 17 jaar mogen zelf beslissen of zij zich willen laten vaccineren; kinderen tussen 12 en 15 beslissen samen met de ouders waarbij de wens van het kind leidend is. Met het oog hierop heeft VWS(Ministerie van Volksgezondheid, Welzijn en Sport ) de RIVM Corona Gedragsunit gevraagd inzicht te geven in de vaccinatiebereidheid van zowel kinderen als ouders; en factoren die samenhangen met deze keuze.
On 28 May 2021, the Pfizer/BioNTech vaccine was approved by the European Medicines Agency (EMA) for use in young people aged 12–15 years. The vaccine had previously already been approved for immunisation of people aged 16 years and older. On 9 June 2021, following an advisory report by the Health Council of the Netherlands, it was decided to offer the Pfizer/BioNTech vaccine to children and adolescents aged 12–18 years who were in medical risk groups. On 30 June 2021, following a new advisory report by the Health Council, it was decided that this vaccine should also be offered to healthy children and adolescents aged 12–18 years. Adolescents aged 16 and 17 years are allowed to decide for themselves whether they want to be vaccinated; children aged 12–15 years decide in consultation with their parents, in which the child’s preference is leading. In view of these developments, the Ministry of Health, Welfare and Sport (VWS) has asked the RIVM COVID-19 Behavioural Unit to offer insight into the willingness to vaccinate among children as well as a adults, and the factors associated with this choice.
On 28 May 2021, the Pfizer/BioNTech vaccine was approved by the European Medicines Agency (EMA) for use in young people aged 12–15 years. The vaccine had previously already been approved for immunisation of people aged 16 years and older. On 9 June 2021, following an advisory report by the Health Council of the Netherlands, it was decided to offer the Pfizer/BioNTech vaccine to children and adolescents aged 12–18 years who were in medical risk groups. On 30 June 2021, following a new advisory report by the Health Council, it was decided that this vaccine should also be offered to healthy children and adolescents aged 12–18 years. Adolescents aged 16 and 17 years are allowed to decide for themselves whether they want to be vaccinated; children aged 12–15 years decide in consultation with their parents, in which the child’s preference is leading. In view of these developments, the Ministry of Health, Welfare and Sport (VWS) has asked the RIVM COVID-19 Behavioural Unit to offer insight into the willingness to vaccinate among children as well as a adults, and the factors associated with this choice.
Description
Publisher
Rijksinstituut voor Volksgezondheid en Milieu RIVM